Ekso Bionics Holdings, Inc. (EKSO)
USD 0.63
(-11.99%)
USD 0.63
(-11.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -13.19 Million USD | 13.94% |
| 2022 | -14.03 Million USD | -5.94% |
| 2021 | -9.09 Million USD | -27.08% |
| 2020 | -15.06 Million USD | 35.2% |
| 2019 | -11.05 Million USD | 35.01% |
| 2018 | -24.89 Million USD | 6.04% |
| 2017 | -26.74 Million USD | 9.32% |
| 2016 | -21.59 Million USD | -49.4% |
| 2015 | -18.64 Million USD | -28.17% |
| 2014 | -32.58 Million USD | -154477.98% |
| 2013 | -10.49 Million USD | 99.92% |
| 2012 | -14.13 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.93 Million USD | 34.42% |
| 2024 Q3 | -1.58 Million USD | 18.46% |
| 2024 Q1 | -2.85 Million USD | -19.94% |
| 2023 Q3 | -2.58 Million USD | 36.1% |
| 2023 Q4 | -2.77 Million USD | -7.27% |
| 2023 FY | - USD | 13.94% |
| 2023 Q1 | -4.03 Million USD | 9.58% |
| 2023 Q2 | -4.04 Million USD | -0.2% |
| 2022 Q4 | -4.46 Million USD | -28.36% |
| 2022 FY | - USD | -5.94% |
| 2022 Q1 | -4.36 Million USD | 8.71% |
| 2022 Q3 | -3.48 Million USD | -20.04% |
| 2022 Q2 | -2.89 Million USD | 33.54% |
| 2021 Q4 | -4.77 Million USD | -64.7% |
| 2021 Q3 | -2.9 Million USD | 5.6% |
| 2021 Q2 | -3.07 Million USD | 12.92% |
| 2021 Q1 | -3.52 Million USD | -33.32% |
| 2021 FY | - USD | -27.08% |
| 2020 Q2 | -2.42 Million USD | 51.49% |
| 2020 Q4 | -2.64 Million USD | -58.79% |
| 2020 Q3 | -1.66 Million USD | 31.29% |
| 2020 FY | - USD | 35.2% |
| 2020 Q1 | -5 Million USD | -67.54% |
| 2019 Q3 | -4.13 Million USD | 12.94% |
| 2019 Q1 | -4.8 Million USD | 8.5% |
| 2019 Q2 | -4.74 Million USD | 1.23% |
| 2019 Q4 | -2.98 Million USD | 27.72% |
| 2019 FY | - USD | 35.01% |
| 2018 Q2 | -7.14 Million USD | 11.4% |
| 2018 FY | - USD | 6.04% |
| 2018 Q4 | -5.24 Million USD | 10.53% |
| 2018 Q3 | -5.86 Million USD | 17.85% |
| 2018 Q1 | -8.06 Million USD | -98.6% |
| 2017 Q3 | -7.42 Million USD | 2.02% |
| 2017 Q4 | -4.05 Million USD | 45.31% |
| 2017 FY | - USD | 9.32% |
| 2017 Q1 | -7.66 Million USD | 7.97% |
| 2017 Q2 | -7.57 Million USD | 1.19% |
| 2016 Q2 | -7.39 Million USD | 19.49% |
| 2016 FY | - USD | -49.4% |
| 2016 Q4 | -8.33 Million USD | -74.52% |
| 2016 Q3 | -4.77 Million USD | 35.47% |
| 2016 Q1 | -9.18 Million USD | -37.94% |
| 2015 Q1 | -3.91 Million USD | 19.74% |
| 2015 FY | - USD | -28.17% |
| 2015 Q4 | -6.66 Million USD | -28.55% |
| 2015 Q3 | -5.18 Million USD | 4.46% |
| 2015 Q2 | -5.42 Million USD | -38.62% |
| 2014 Q3 | -3.74 Million USD | 9.74% |
| 2014 Q2 | -4.15 Million USD | -10.82% |
| 2014 Q1 | -3.74 Million USD | -62163.77% |
| 2014 FY | - USD | -154477.98% |
| 2014 Q4 | -4.87 Million USD | -30.1% |
| 2013 FY | - USD | 99.92% |
| 2013 Q4 | -6015.00 USD | -319.75% |
| 2013 Q1 | -3833.00 USD | -147.29% |
| 2013 Q2 | -23.16 Thousand USD | -504.3% |
| 2013 Q3 | -1433.00 USD | 93.81% |
| 2012 Q3 | -1200.00 USD | 75.3% |
| 2012 FY | - USD | 0.0% |
| 2012 Q2 | -4858.00 USD | 0.0% |
| 2012 Q4 | -1550.00 USD | -29.17% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 71.077% |
| AngioDynamics, Inc. | -14.29 Million USD | 7.655% |
| AtriCure, Inc. | -8.1 Million USD | -62.757% |
| Avinger, Inc. | -16.34 Million USD | 19.259% |
| Azenta, Inc. | 55.15 Million USD | 123.931% |
| BioLife Solutions, Inc. | -45.23 Million USD | 70.825% |
| The Cooper Companies, Inc. | 882.8 Million USD | 101.495% |
| Daxor Corporation | 329.74 Thousand USD | 4102.547% |
| Femasys Inc. | -13.16 Million USD | -0.217% |
| GlucoTrack, Inc. | -7.09 Million USD | -86.123% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 239.029% |
| Hologic, Inc. | 1.29 Billion USD | 101.018% |
| ICU Medical, Inc. | 307.69 Million USD | 104.289% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 100.551% |
| KORU Medical Systems, Inc. | -9.39 Million USD | -40.41% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 126.94% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -100.726% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -100.726% |
| Masimo Corporation | 236.7 Million USD | 105.576% |
| Microbot Medical Inc. | -10.63 Million USD | -24.111% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 183.688% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 105.703% |
| Nephros, Inc. | -1.37 Million USD | -857.07% |
| NovoCure Limited | -175.86 Million USD | 92.495% |
| NEXGEL, Inc. | -2.73 Million USD | -383.443% |
| NEXGEL, Inc. | -2.73 Million USD | -383.443% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 84.741% |
| OraSure Technologies, Inc. | 76.15 Million USD | 117.33% |
| Pro-Dex, Inc. | 8.33 Million USD | 258.382% |
| Pulse Biosciences, Inc. | -42.36 Million USD | 68.848% |
| Predictive Oncology Inc. | -13.18 Million USD | -0.121% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | -425.408% |
| QuidelOrtho Corporation | 545.6 Million USD | 102.419% |
| Repligen Corporation | 124.29 Million USD | 110.619% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -4465.25% |
| STAAR Surgical Company | 33.22 Million USD | 139.728% |
| Sharps Technology, Inc. | -8.98 Million USD | -46.965% |
| Utah Medical Products, Inc. | 24.8 Million USD | 153.207% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 105.689% |
| Jin Medical International Ltd. | 3.44 Million USD | 483.341% |